Institute Of Hematology & Blood Diseases Hospital, China

This early study is testing a new treatment called CD5CART for people with relapsed or refractory CD5-positive blood cancers. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer cells, and then infusing them ba…

This study tests a new combination of drugs for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The experimental drug is a liposomal form of mitoxantrone, given with standard chemotherapy and rituximab. The trial has two parts: first, finding the safest dose, t…

This phase 2 study is testing a combination of two drugs, mosunetuzumab and zeprumetostat, in about 80 people with follicular lymphoma, a type of blood cancer. The trial includes patients who are newly diagnosed (with high or low tumor burden) and those whose cancer has come back…

This study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for…

This study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML). The goal is to see if this triple therapy can improve remission rates and survival compared to standard treat…

This phase 2 trial is testing a combination of two drugs—CM336 (a bispecific antibody) and isatuximab (a monoclonal antibody)—in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function…

This phase 2 trial tests whether adding venetoclax to standard intensive chemotherapy improves outcomes for adults with acute myeloid leukemia (AML). The study will enroll 380 patients aged 14 to 60 to see which genetic subtypes benefit most. Researchers hope to personalize treat…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people with untreated follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the combo shrinks or eliminates tumors. About 34 adults with stage II bulky or stage…

This study is testing a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. About 37 adults aged 18 to 80 will receive the drugs, and those at higher risk may also …

This study is for adults aged 14 to 60 with a specific, high-risk type of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding targeted drugs (olverembatinib or gecacitinib) and venetoclax to standard chemotherapy can help more patients achieve …

This study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with acute myeloid leukemia (AML) who have a specific genetic change called FLT3 mutation. The goal is to see if this triple therapy can improve remission rates and…

This study is testing a new combination of low-intensity chemotherapy and targeted immunotherapy for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Participants will receive a third-generation TKI drug (olverembatinib) and may…

This early-phase trial tests a new treatment called BAFF-R CAR-T for people with B-cell lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells carrying a protein called BAFF-…

This study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve…

This study tests whether adding rituximab to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite prior treatments. About 224 participants will receive either the combo or eltrombopag alone, and resea…

This study tests whether a mobile app can help children with acute lymphoblastic leukemia (ALL) keep their white blood cell counts in a healthy range during maintenance therapy. About 100 children who are already doing well on the app will be randomly assigned to continue using i…

This registry follows 100 adults and teens with hemophilia A or B who are prescribed marstacimab, a once-weekly shot under the skin. The main goals are to see if patients prefer this shot over IV treatments and to measure treatment burden after 6 months. Researchers will also tra…

This Phase 3 trial is testing whether a higher dose of the chemotherapy drug cytarabine, given with standard drugs, improves survival for people with acute myeloid leukemia (AML) that has a specific genetic change called RUNX1-RUNX1T1. The study will enroll 300 adults aged 14 to …

This phase 2 trial is testing a drug called CM336 in 21 people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. CM336 is a bispecific antibody that helps the immune system target and destroy the cells making these proteins. The study…

This early study tests whether zoledronic acid, a drug usually used for bone health, can help people with a rare inherited anemia called congenital dyserythropoietic anemia (CDA). Only 2 adults with CDA who have low hemoglobin or need regular transfusions will receive 4 doses of …

This early-stage trial tests whether a patient's own immune cells, modified to target HIV (called CAR-T cells), can help control the virus without daily medication. Only 3 people with well-controlled HIV will receive the treatment. The main goal is to check safety, but researcher…

This study tests whether adding CAR-T cells to standard chemotherapy can help adults newly diagnosed with a certain type of leukemia (Ph-negative B-ALL) achieve deeper remission and need fewer chemo cycles. About 77 participants will receive CAR-T cells after initial chemo. The g…

This clinical trial is testing a new treatment approach for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The treatment combines targeted drugs (olverembatinib and venetoclax) with reduced-intensity chemotherapy, followed by …

This study is testing a new treatment for young adults (18-55) newly diagnosed with multiple myeloma. It uses a patient's own immune cells, engineered to attack the cancer (BCMA-CART), either alone or combined with a stem cell transplant. The goal is to see if this approach can w…

This study tests whether a newer, targeted drug combination (venetoclax plus azacitidine) works better than standard intensive chemotherapy for adults aged 55 to 75 with acute myeloid leukemia (AML). About 240 participants will be randomly assigned to one of the two treatments. T…

This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had any prior treatment. The goal is to see if the drug can shrink or control the cancer. Participants take the drug by mouth and are monitored fo…

This study looks at growth problems in children with thalassemia, a blood disorder. Researchers will test a program that includes health education, nutrition plans, exercise, and support to help kids grow better. The goal is to improve height, weight, and overall well-being in 36…

This study tests a medicine called prothrombin complex concentrate (PCC) to stop bleeding episodes in people with hemophilia A who have developed inhibitors (antibodies that block standard treatment). Thirty participants aged 12 to 65 will receive PCC on-demand during bleeding, w…

This study compares two antibody drugs—daratumumab and rituximab—in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The goal is to see which drug works better at raising platelet counts and reducing bleeding risk…

This study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low or came back after steroid treatment. About 160 participants will receive either t…

This early-phase study tests whether stem cells from donated umbilical cord blood can safely help people whose blood counts stay dangerously low after CAR-T therapy. The trial will enroll 15 adults with leukemia, lymphoma, or myeloma. Participants receive weekly stem cell infusio…

This study tests a new drug, daratumumab, against an older one, rituximab, in children aged 6 to 17 with immune thrombocytopenia (ITP) that didn't improve with steroids. ITP causes low platelets and easy bleeding. The goal is to see which drug works better at raising platelet cou…

This phase 2 trial tests whether combining rituximab with daratumumab can raise platelet counts in adults with immune thrombocytopenia (ITP) who have not responded to steroids. Twenty participants will receive one dose of rituximab and eight doses of daratumumab over eight weeks.…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This study looks at whether liposomal amphotericin B (AmBisome) can safely treat breakthrough fungal infections in children and teens with blood cancers who are already on antifungal prevention. About 38 participants will receive the drug as part of their regular care, and resear…

This study tests whether sulforaphane, a compound found in broccoli sprouts, can help blood cells recover faster after a cord blood transplant in adults with leukemia or related blood cancers. The trial will involve 36 patients and focus on safety and how quickly neutrophils (a t…

This phase II trial tests whether the drug chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either take chidamide pills or receive standard observa…

This early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people newly diagnosed with a rare type of lymphoma that affects the spleen. The goal is to see how well the treatment shrinks or controls the cancer and to check for side effects. Abo…

This early-stage trial is testing a new type of immune cell therapy called supCD7 CART cells in 12 adults with relapsed or refractory CD7-positive blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia). The cells are designed to target and kill cancer cells that carry…

This study is testing a new treatment approach for adults newly diagnosed with a specific type of leukemia (Ph-negative B-cell acute lymphoblastic leukemia). The treatment combines low-dose chemotherapy with several targeted immunotherapy drugs. The goal is to see if this gentler…

This study tests an experimental drug called Anti-CD38 antibody in 60 children aged 6 and older who have immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The participants have not responded well to standard treatments.…

This early-phase study tests whether a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on myeloma cells is safe for people whose cancer has returned or stopped responding to treatment. Nine participants will receive the therapy and be monitored for side e…

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers…

This phase 2 trial tests thalidomide, a drug once used for other conditions, in 48 people with symptomatic large granular lymphocytic (LGL) leukemia. Participants start on thalidomide alone; if it doesn't work well enough, methotrexate is added. The goal is to see if thalidomide …

This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) to treat people with ultra high-risk multiple myeloma, a blood cancer that is hard to treat. The 20 participants will receive their own stem cells after high-dose chemotherapy, followed by a …

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This study tests a combination of two antifungal drugs—liposomal amphotericin B plus either posaconazole or isavuconazole—in 60 adults with blood cancers who also have a serious fungal infection called mucormycosis. The goal is to see if the combo can clear the infection better a…

This early-phase trial tests whether methylene blue, a dye used in medicine for other conditions, can safely treat two serious side effects of certain cancer immunotherapies: cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS). The study will enroll 18 adults…

This study compares two strategies for people with higher-risk myelodysplastic syndrome (MDS): getting a donor stem cell transplant right away versus receiving one to two cycles of chemotherapy first (called bridging therapy) before the transplant. The goal is to see if immediate…

This phase 2 trial tests whether combining radiation with a bispecific antibody called CM336 can safely treat solitary bone plasmacytoma, a rare plasma cell tumor that often turns into multiple myeloma. The study will enroll 21 adults with mild bone marrow involvement. Researcher…

This clinical trial is testing a new combination of drugs for children and teens with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study uses a targeted drug called olverembatinib along with immune therapy (blinat…

This early-phase study is testing a new type of immune cell therapy called universal CD7 CAR-T (uCD7 CART) in people with relapsed or refractory acute myeloid leukemia (AML) or T-cell leukemia/lymphoma. The cells are designed to target and kill cancer cells that carry the CD7 pro…

This study uses a non-invasive brain imaging technique called fNIRS to see how anemia affects thinking and memory. Researchers will measure brain activity in 323 adults with different types of anemia and compare it to cognitive test scores. The goal is to identify which brain reg…

This study watches 200 people with aplastic anemia who are getting ATG/ALG treatment for the first time. Researchers will track side effects like serum sickness, organ damage, and infusion reactions to learn how common and severe they are. The goal is to create better guidelines …

This study follows 500 children aged 6-17 diagnosed with immune thrombocytopenia (ITP), a rare autoimmune disease that causes low platelet counts and bleeding. Researchers will collect data on symptoms, treatments, and outcomes over several years to build a model that predicts ho…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This study looks at 60 people getting a stem cell transplant to see if their autonomic nervous system (which controls things like heart rate and sweating) can help predict a serious complication called graft-versus-host disease (GvHD). Participants will have simple nerve tests be…

This study aims to track the health of 1,500 elderly people, some in nursing homes and some at home. Researchers will look at chronic diseases, cancers, and other priority health issues. No treatments or drugs are given—just observation and health check-ups.